28 Results for "

IDE

" in MedChemExpress (MCE) Product Catalog:
Products (28)

28 Results for "IDE" in MCE Product Catalog:

  • Targets Recommended:
Cat. No.: HY-P85666
Synonyms: IDE; Insulin-degrading enzyme; Abeta-degrading protease; Insulin protease; Insulinase; Insulysin

Host:  

Mouse

Application:  

WB, IHC-P, ICC/IF

Reactivity:  

Human, Hamster

loading...
    loading...
Cat. No.: HY-182280
Target:  

Insulin Receptor

Research Areas:  

Metabolic Disease

BDM71230 is an orally active inducer of insulin-degrading enzyme (IDE), with an EC50 of 1.9 μM against human IDE. BDM71230 binds to the interface of IDE dimers and enhances the catalytic activity of IDE via steric effects. BDM71230 can potentiate the hydrolytic effect of IDE on insulin and slightly attenuate the hypoglycemic effect of insulin. BDM71230 serves as a pharmacological tool for investigating IDE function and is applicable to studies related to glucose intolerance .
loading...
    loading...
Cat. No.: HY-P70291
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: IDE; Insulin Protease; Insulin Degrading Enzyme; Abeta-Degrading Protease; Insulin-Degrading Enzyme; Insulinase; Insulysin; CDNA FLJ35968 Fis, Clone TESTI2013053, Highly Similar To INSULIN-DEGRADING ENZYME
Species:  
Human
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-W038421
CAS No.: 141556-42-5
Synonyms: 1,3-Dimesityl-1H-imidazol-3-ium-2-IDE
Target:  

MOFs

Research Areas:  

Others

1,3-Bis(2,4,6-trimethylphenyl)-1,3-dihydro-2H-imidazol-2-ylidene (1,3-Dimesityl-1H-imidazol-3-ium-2-ide) is a metal-organic framework (MOF).
loading...
    loading...
Cat. No.: HY-110197A
Target:  

IDE

Research Areas:  

Metabolic Disease

6bK formate is a selective insulin-degrading enzyme (IDE) inhibitor with an IC50 of 50 nM. 6bK formate binds to the distal pocket of IDE, thereby blocking substrate binding, peptide unfolding and cleavage processes, and reducing the degradation of insulin, glucagon and amylin. 6bK formate improves oral glucose tolerance but impairs intraperitoneal glucose tolerance. 6bK formate can be used in research related to type 2 diabetes .
loading...
    loading...
Cat. No.: HY-110197R
CAS No.: 1774353-12-6
Target:  

Reference Standards IDE

Research Areas:  

Metabolic Disease

6bK TFA (Standard) is the analytical standard of 6bK (TFA) (HY-110197). This product is intended for research and analytical applications. 6bK TFA is a potent and selective insulin degrading enzyme (IDE) inhibitor with an IC50 value of 50 nM. 6bK TFA increases circulating insulin in high-fat-fed mice. Acute administration of 6bK TFA enhances glucose tolerance to oral glucose, notably to a greater extent in high-fat-fed mice. 6bK TFA can be used for type 2 diabetes research .
loading...
    loading...
Cat. No.: HY-P80191
Synonyms: Insulin-degrading enzyme, Abeta-degrading protease, Insulin protease, Insulysin, Insulinase, IDE

Host:  

Rabbit

Application:  

WB, IHC-P, IHC-F, IF-Tissue

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
Cat. No.: HY-P992056

Target:  

Autophagy

Research Areas:  

Cancer

Anti-Human/Mouse LY6E Antibody (9B12) is a high-affinity, multi-target antibody that binds specifically to LY6E. Anti-Human/Mouse LY6E Antibody (9B12) binds specifically to cell-surface LY6E and enters lysosomes via lipid raft-dependent endocytosis, thereby effectively inhibiting the growth of various LY6E-expressing solid tumors (such as breast cancer and lung cancer) in both in vitro and in vivo models. Anti-Human/Mouse LY6E Antibody (9B12) exerts a dual mechanism of action: on one hand, it blocks the interaction between PILRα and CD8α, specifically reduces the survival rate of peripheral CD8 + T cells and induces their activation, breaking the state of cellular quiescence; on the other hand, it recognizes and immunoprecipitates IDE under both non-denaturing and denaturing conditions, which is applicable to studies on the subcellular localization and protein interactions of IDE. The regulatory effect of Anti-Human/Mouse LY6E Antibody (9B12) on CD8 + T cells strictly depends on the presence of PILRα, and it does not affect CD4 + T cells or T cell development in the thymus, exhibiting high specificity .
loading...
    loading...